Patents by Inventor Josh SNYDER

Josh SNYDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
    Publication number: 20240043556
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 10, 2023
    Publication date: February 8, 2024
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
  • Antibody drug conjugates (ADC) that bind to CD37 proteins
    Patent number: 11633500
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: April 25, 2023
    Assignee: AGENSYS, INC.
    Inventors: Daniel Sousa Pereira, Faisal Hayat Malik, Josh Snyder, Leslie Renee Butterworth, Ssucheng Jeff Hsu, Peng Yang, Claudia Isabel Guevara
  • Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
    Patent number: 11634503
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: April 25, 2023
    Assignees: AGENSYS, INC., SEAGEN INC.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS
    Publication number: 20210145979
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: April 17, 2020
    Publication date: May 20, 2021
    Applicant: AGENSYS, INC.
    Inventors: Daniel Sousa PEREIRA, Faisal Hayat MALIK, Josh SNYDER, Leslie Renee BUTTERWORTH, Ssucheng Jeff HSU, Peng YANG, Claudia Isabel GUEVARA
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
    Publication number: 20210095043
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: May 4, 2020
    Publication date: April 1, 2021
    Applicants: AGENSYS, INC., SEAGEN INC.
    Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
  • Antibody drug conjugates (ADC) that bind to FLT3 proteins
    Patent number: 10751422
    Abstract: Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: August 25, 2020
    Assignee: AGENSYS, INC.
    Inventors: Nandini Rudra-Ganguly, Christine Lowe, Faisal Hayat Malik, Sung Ju Moon, Josh Snyder, Hector Avina, Cyrus Virata, Linnette Capo, Gao Liu
  • Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
    Patent number: 10669348
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: June 2, 2020
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • Antibody drug conjugates (ADC) that bind to CD37 proteins
    Patent number: 10646583
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: May 12, 2020
    Assignee: AGENSYS, INC.
    Inventors: Daniel Sousa Pereira, Faisal Hayat Malik, Josh Snyder, Leslie Renee Butterworth, Ssucheng Jeff Hsu, Peng Yang, Claudia Isabel Guevara
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
    Publication number: 20180251566
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: February 13, 2018
    Publication date: September 6, 2018
    Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS
    Publication number: 20180236096
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 23, 2018
    Inventors: Daniel Sousa PEREIRA, Faisal Hayat MALIK, Josh SNYDER, Leslie Renee BUTTERWORTH, Ssucheng Jeff HSU, Peng YANG, Claudia Isabel GUEVARA
  • Antibody drug conjugates (ADC) that bind to FLT3 proteins
    Patent number: 9974865
    Abstract: Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: May 22, 2018
    Assignee: AGENSYS, INC.
    Inventors: Christine Lowe, Nandini Rudra-Ganguly, Faisal Hayat Malik, Sung Ju Moon, Josh Snyder, Hector Avina, Cyrus Virata, Linnette Capo, Gao Liu
  • Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
    Patent number: 9926376
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: March 27, 2018
    Assignees: Agensys, Inc., Seattle Genetics Inc.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • Antibody drug conjugates (ADC) that bind to CD37 proteins
    Patent number: 9925273
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 27, 2018
    Assignee: AGENSYS, INC.
    Inventors: Daniel Sousa Pereira, Faisal Hayat Malik, Josh Snyder, Leslie Renee Butterworth, Ssucheng Jeff Hsu, Peng Yang, Claudia Isabel Guevara
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO FLT3 PROTEINS
    Publication number: 20180037657
    Abstract: Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 9, 2016
    Publication date: February 8, 2018
    Applicant: AGENSYS, INC.
    Inventors: Nandini RUDRA-GANGULY, Christine LOWE, Faisal Hayat MALIK, Sung Ju MOON, Josh SNYDER, Hector AVINA, Cyrus VIRATA, Linnette CAPO, Gao LIU
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
    Publication number: 20160369003
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 30, 2016
    Publication date: December 22, 2016
    Applicants: AGENSYS, INC., Seattle Genetics, Inc.
    Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO FLT3 PROTEINS
    Publication number: 20160272716
    Abstract: Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 9, 2016
    Publication date: September 22, 2016
    Inventors: Christine Lowe, Nandini Rudra-Ganguly, Faisal Hayat Malik, Sung Ju Moon, Josh Snyder, Hector Avina, Cyrus Virata, Linnette Capo, Gao Liu
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS
    Publication number: 20160051694
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: July 30, 2014
    Publication date: February 25, 2016
    Inventors: Daniel Sousa PEREIRA, Faisil Hayat MALIK, Josh SNYDER, Leslie Renee BUTTERWORTH, Ssucheng Jeff HSU, Peng YANG, Claudia Isabel GUEVARA
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
    Publication number: 20150238633
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: February 27, 2015
    Publication date: August 27, 2015
    Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
  • Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
    Patent number: 8968742
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: March 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
    Patent number: RE47103
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: October 30, 2018
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia